CYP2C8

CYP2C8 is a member of the Cytochrome P450 family of enzymes. These enzymes are responsible for the metabolism of a wide variety of substances, including many drugs and endogenous compounds. CYP2C8, in particular, is involved in the metabolism of more than 60% of all marketed drugs.

Function

CYP2C8 is primarily found in the liver and is responsible for the oxidation of xenobiotic and endogenous compounds, including fatty acids and drugs. The enzyme is involved in the metabolism of several clinically important drugs, including paclitaxel, repaglinide, rosiglitazone, and pioglitazone. It also metabolizes certain endogenous compounds, such as arachidonic acid and linoleic acid.

Genetic variation

There are several known genetic variants of CYP2C8, which can affect the enzyme's activity and, consequently, the metabolism of drugs. These variants can lead to differences in drug response among individuals. For example, the CYP2C8*3 variant has been associated with increased metabolism of paclitaxel and rosiglitazone, potentially affecting the efficacy and safety of these drugs.

Clinical significance

Given its role in drug metabolism, variations in CYP2C8 can have significant clinical implications. For instance, individuals with certain CYP2C8 variants may require dose adjustments for drugs metabolized by this enzyme to avoid adverse drug reactions or therapeutic failure. Furthermore, the enzyme's involvement in the metabolism of endogenous compounds suggests that CYP2C8 may also play a role in certain diseases, such as cardiovascular disease and cancer.

See also

• Cytochrome P450
• Pharmacogenomics
• Drug metabolism

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!